{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:08:03Z","timestamp":1785276483297,"version":"3.55.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T00:00:00Z","timestamp":1330387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aims of the present article were to study clinical features and to analyse them in different drug class associated with Stevens\u2013Johnson syndrome (SJS) in a tertiary care hospital in Gujarat, India.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A prospective hospital\u2010based study was carried out over a period of 3\u2009years (June 2007 to September 2009) at Sheth Vadilal Hospital, Ahmedabad, India. The diagnosis of SJS was made mainly on the basis of the clinical findings, which included extensive erythema multiforme, purpuric lesions with bullae and detachment of skin involving at least two mucous membranes. Further, in each patient suspected with SJS, various laboratory tests such as complete blood count, liver function tests, metabolic panel, chest X\u2010ray and other serological test were carried out. SJS was confirmed on the basis of most widely accepted Bastuji\u2010Garin definition. Causality assessment was performed using the Naranjo scale. Only \u2018probable\u2019 and \u2018definite\u2019 reactions were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Antibacterials for systemic use, anti\u2010inflammatory and antirheumatic products and antiepileptics were the drug classes most commonly associated (8 of 29 cases, each) with SJS. Individually, ibuprofen was involved in the highest number of cases (five cases, 17.2%), followed by carbamazepine (four cases, 13.8%) . The mean duration of developing SJS symptoms was 15.9 days (SD = 8.7 days) and improvement after treatment was 14.2 days (SD = 4.6 days). The duration of appearing SJS symptoms varied significantly between different classes of drugs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The appearance of SJS symptom started within 10\u2009days for anti\u2010inflammatory and antibacterial compared with 24\u2009days of antiepileptic agents. All the patients with antiepileptic agent\u2013induced SJS had 7% to 9% of detached body surface area. In two patients, SJS progressed to toxic epidermal necrolysis and of which one led to death and the other developed long\u2010term complication of conjunctival xerosis. A total of six patients developed long\u2010term complications: four patients had conjunctival synechia, one patient had conjunctival xerosis and one patient had urethral stricture.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>More than 80% of the SJS events were induced by antibacterial, anti\u2010inflammatory and antiepileptic agents with same frequency. The duration of the appearance of SJS symptoms significantly varied between different drug classes and started within 10\u2009days for anti\u2010inflammatory and antibacterial compared with 24\u2009days of antiepileptic agents. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3212","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T13:24:26Z","timestamp":1330435466000},"page":"384-395","source":"Crossref","is-referenced-by-count":13,"title":["Drug\u2010induced Stevens\u2013Johnson syndrome: case series from tertiary care centre in Gujarat"],"prefix":"10.1002","volume":"21","author":[{"given":"Damodar","family":"Bang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Smt. N.H.L. Municipal Medical College  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Institute of Pharmacy, Nirma University  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyesh","family":"Thakker","sequence":"additional","affiliation":[{"name":"Patient Safety Unit Shrimati Kaumudiniben Health Outcome Research Group  Dhrangadhra Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Smt. N.H.L. Municipal Medical College  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit D.","family":"Raval","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Institute of Pharmacy, Nirma University  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"issue":"6","key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens\u2010Johnson syndrome. An epidemiologic study from West Germany","volume":"127","author":"Schopf E","year":"1991","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550310007166"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250049006"},{"issue":"1","key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","article-title":"Treatment of severe drug reactions: Stevens\u2010Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain PD","year":"2002","journal-title":"Dermatol Online J"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427070-00004"},{"key":"e_1_2_6_8_1","first-page":"644","volume-title":"Fitzpatrick's dermatology in general medicine","author":"Fritsch PO","year":"1999"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690170041005"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1996.d01-924.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.6.683"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-199704000-00005"},{"issue":"11","key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.1995.01690230046008","article-title":"Clinicopathologic correlation in erythema multiforme and Stevens\u2010Johnson syndrome","volume":"131","author":"Cote B","year":"1995","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250043005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001060-00003"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(85)70207-1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660330082014"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.45901.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05418-X"},{"key":"e_1_2_6_21_1","unstructured":"National Pharmacovigilance Program.National Pharmacovigilance Protocol Ministry of Health & Family Welfare Govt. of India Journal [serial on the Internet]. Date [cited 2011: Available from:www.jipmer.edu\/charu\/NPVP"},{"issue":"1","key":"e_1_2_6_22_1","first-page":"16","article-title":"Adverse drug reactions among inpatients in a north Indian referral hospital","volume":"13","author":"Uppal R","year":"2000","journal-title":"Natl Med J India"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00096.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb01017.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_6_26_1","unstructured":"ATC\/DDD Methodology: History. [Internet]: WHO Collaborating Centre for Drug Statistics Methodology; [cited];1976; Available from:http:\/\/www.whocc.no\/atc_ddd_methodology\/history\/"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.41369"},{"issue":"2","key":"e_1_2_6_28_1","first-page":"115","article-title":"Drug\u2010induced Stevens\u2010Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\u2010TEN overlap: A multicentric retrospective study","volume":"57","author":"Barvaliya M","journal-title":"J Postgrad Med"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.048"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0379"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050492"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-199605000-00009"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90297-2"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb02814.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12388434"},{"issue":"5","key":"e_1_2_6_37_1","first-page":"537","article-title":"Analysis of treatments and deceased cases of severe adverse drug reactions\u2010\u2010analysis of 46 cases of Stevens\u2010Johnson syndrome and toxic epidermal necrolysis","volume":"58","author":"Yamane Y","year":"2009","journal-title":"Arerugi"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00490.x"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3212","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:59:32Z","timestamp":1696935572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/pds.3212"],"URL":"https:\/\/doi.org\/10.1002\/pds.3212","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]}}}